通过网络药理和生物信息学方法探索乌尔索酸对动脉样硬化的作用机制
Nan Huang1, Qichang Xing, Wencan Li
1Clinical Pharmacy, Xiangtan Center Hospital, Xiangtan, China.
Medicine
|July 28, 2023
概括
乌尔索酸 (UA) 通过调节雄激素受体 (AR) 和互白素-1β (IL1B) 基因甲基化来向动脉样硬化. 这项研究通过网络药理学和生物信息学分析揭示了UA在治疗动脉样硬化的潜在机制.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物信息学是一种生物信息学.
- 遗传学 是一个遗传学.
背景情况:
- 动脉样硬化是一种复杂的炎症性疾病.
- 乌尔索酸 (UA) 是一种天然化合物,显示出潜在的治疗益处.
- 了解UA在动脉样硬化中的分子机制至关重要.
研究的目的:
- 阐明乌尔索酸 (UA) 在治疗动脉样硬化的深层机制.
- 确定关键的目标基因和涉及UA作用的途径.
- 探索基因甲基化在UA治疗效果中的作用.
主要方法:
- 使用了网络药理学和生物信息学分析.
- 从多个数据库中确定UA目标基因和动脉样硬化相关基因.
- 用STRING和Cytoscape构建和分析了蛋白质与蛋白质相互作用网络.
- 进行了基因本体学 (GO) 和基因和基因组的京都百科全书 (KEGG) 丰富分析.
- 进行甲基化和ceRNA分析以验证发现.
主要成果:
- 乌尔索酸证明了动脉样硬化治疗的145个潜在点.
- 关键的生物过程包括对脂多糖的反应和炎症反应调节.
- 重要的途径涉及TNF和AGE-RAGE信号传递.
- 确定了雄激素受体 (AR) 和互白素-1β (IL1B) 作为核心向基因.
- 在动脉样硬化中,AR甲基化升高,而IL1B甲基化降低.
- AR和IL1B分别与43个和3个小RNA相关.
结论:
- 乌尔索酸 (UA) 可以通过向雄激素受体 (AR) 和互白素-1β (IL1B) 来治疗动脉样硬化.
- UA的机制可能涉及调节AR和IL1B的甲基化状态.
- 这项研究为开发基于UA的动脉样硬化疗法提供了基础.
相关概念视频
01:26Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
01:30Atherosclerosis I: Introduction
11
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
11
01:28Structure-Activity Relationships and Drug Design
770
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
770
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:23Atherosclerosis IV: Nursing Management
23
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
23
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
565
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
565